Business Context and Reporting Period
Company: Hemispherx Biopharma, Inc. (Note: Input metadata referenced "AIM Immunotech Inc.", but the filing text identifies the registrant as Hemispherx Biopharma, Inc.)
Reporting Period: Fiscal year ended December 31, 2010
Business Overview: A specialty pharmaceutical company focused on clinical development of immune system enhancing therapies. The company's primary assets are Ampligen (experimental RNA drug for Chronic Fatigue Syndrome and influenza adjuvant) and Alferon N Injection (FDA-approved natural interferon for genital warts, currently not in commercial sales due to inventory expiration). The company also develops Alferon LDO (oral interferon for influenza).
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 Value | 2009 Value |
|---|---|---|
| Total Revenues | $135,000 | $111,000 |
| Net Loss | $(13,136,000) | $(7,180,000) |
| Loss Per Share (Basic/Diluted) | $(0.10) | $(0.07) |
| Research & Development Expenses | $7,613,000 | $6,995,000 |
| General & Administrative Expenses | $7,568,000 | $5,796,000 |
| Cash, Cash Equivalents & Marketable Securities | $44,387,000 | $58,072,000 |
| Working Capital | $33,842,000 | $55,789,000 |
| Accumulated Deficit | $(217,725,000) | $(204,589,000) |
Note: The company has no debt listed on the balance sheet other than capital lease obligations ($157,000 total). Revenues are derived solely from Ampligen cost-recovery clinical treatment programs; commercial sales of Alferon N Injection have been halted since March 2008.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately 83% (from $7.2M to $13.1M). This was driven by increased operating expenses, partially offset by a significant non-cash gain from the revaluation of redeemable warrants ($879,000 in 2010 vs. $6.3M in 2009).
- Expense Growth:
- R&D: Increased 9% to $7.6M, primarily due to costs associated with Alferon LDO development and responding to FDA clinical hold issues.
- G&A: Increased 31% to $7.6M, largely due to $1.4M in legal fees related to a successful judgment against Johannesburg Consolidated Investments and defense of other proceedings.
- Production Costs: Increased 130% to $1.3M due to restarting manufacturing processes and quality control testing.
- Interest Income: Increased significantly to $2.4M (from $67,000) due to a diverse portfolio of short and long-term investments.
- Liquidity: Cash and marketable securities decreased by approximately $13.7M to $44.4M, reflecting operating cash burn of $11.9M.
Guidance, Outlook, and Risks
Regulatory Status & Outlook
- Ampligen (CFS): Received a Complete Response Letter (CRL) from the FDA in November 2009. The FDA requires at least one additional Phase III clinical study (estimated cost $7.2M–$11.1M) to demonstrate efficacy. The company received a one-year extension in December 2010 to file a response. Management is prioritizing the identification of a reliable diagnostic test for CFS before committing to the Phase III study.
- Alferon LDO (Influenza): The FDA lifted a Clinical Hold on December 22, 2010, allowing the Phase II study to proceed. The hold was initially due to concerns over the stability of drug product manufactured from older API lots.
- Alferon N Injection: Commercial sales remain halted. Manufacturing upgrades at the New Brunswick facility are underway, with a target to resume production for potential commercial sales in mid-to-late 2011, pending third-party vendor agreements for packaging and labeling.
Liquidity and Capital Resources
Management anticipates that current cash resources ($44.4M) will fund operations for at least the next four years, absent unexpected circumstances. However, the company may require additional financing to complete clinical trials and regulatory processes. The ability to raise equity is limited by the number of authorized but unissued shares (approx. 32.2M).
Key Risks
- Regulatory Approval: No assurance that Ampligen or Alferon LDO will receive FDA approval. Failure to obtain approval would materially adversely affect operations.
- Manufacturing: Reliance on third-party vendors for final formulation, packaging, and labeling of Alferon N Injection. Failure to secure these agreements could delay commercial sales.
- Legal Proceedings: While several class action lawsuits were settled in early 2011 (paid via insurance), the company faces ongoing litigation risks and potential product liability claims.
- Competition: Significant competition from large pharmaceutical companies with greater resources for product development and marketing.
Investor Verification Checklist
- Ampligen Phase III Feasibility: Verify the company's progress in identifying a reliable diagnostic test for CFS, which is a prerequisite for the required Phase III study.
- Alferon N Manufacturing: Confirm the status of third-party vendor agreements for packaging and labeling required to resume commercial sales in 2011.
- Cash Burn Rate: Monitor quarterly cash usage to ensure the "four-year runway" estimate remains valid given the high cost of the proposed Ampligen Phase III study ($7M–$11M).
- Legal Settlements: Verify that the settlements of the securities class action and shareholder derivative lawsuits (approved in early 2011) were fully covered by insurance and did not result in direct cash outflows.
- Authorized Shares: Assess the risk of dilution or inability to raise capital due to the limited number of authorized but unissued shares (approx. 32.2M).